Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J. Akard L, et al. Among authors: munteanu m. Leuk Lymphoma. 2016;57(3):654-65. doi: 10.3109/10428194.2015.1071486. Epub 2015 Oct 5. Leuk Lymphoma. 2016. PMID: 26436949 Free PMC article.
Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J. Wetzler M, et al. Among authors: munteanu m. Blood Cancer J. 2015 Dec 11;5(12):e376. doi: 10.1038/bcj.2015.104. Blood Cancer J. 2015. PMID: 26657200 Free PMC article. No abstract available.
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. Cortes JE, et al. Among authors: munteanu m. Cancer. 2015 May 15;121(10):1637-44. doi: 10.1002/cncr.29240. Epub 2015 Jan 13. Cancer. 2015. PMID: 25586015 Free PMC article.
Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P Jr, Rosing H, Spiegelstein O, Schellens JH. Nijenhuis CM, et al. Among authors: munteanu m. Invest New Drugs. 2016 Oct;34(5):565-74. doi: 10.1007/s10637-016-0360-9. Epub 2016 May 25. Invest New Drugs. 2016. PMID: 27221729 Free PMC article. Clinical Trial.
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Simpson D, Craig M, Kolibaba K, Issa S, Munteanu M, Victor TW, Flinn IW. Burke JM, et al. Among authors: munteanu m. Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):182-190.e1. doi: 10.1016/j.clml.2016.01.001. Epub 2016 Jan 15. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26875824 Free article. Clinical Trial.
Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
Fraser C, Brown P, Megason G, Ahn HS, Cho B, Kirov I, Frankel L, Aplenc R, Bensen-Kennedy D, Munteanu M, Weaver J, Harker-Murray P. Fraser C, et al. Among authors: munteanu m. J Pediatr Hematol Oncol. 2014 May;36(4):e212-8. doi: 10.1097/MPH.0000000000000021. J Pediatr Hematol Oncol. 2014. PMID: 24072240 Free PMC article. Clinical Trial.
430 results